12262 Federal Register / Vol. 80, No. 44 / Friday, March 6, 2015 / Notices 

and equitable allocation of securities 

and prices to accounts, and provide for 

crossing of buy and sell orders on a fair 

and equitable basis. 

• 12 CFR 151.140 requires Federal 

savings associations to adopt written 

policies and procedures dealing with 

the functions involved in effecting 

securities transactions on behalf of 

customers. These policies and 

procedures must assign responsibility 

for the supervision of employees who 

perform securities trading functions, 

provide for the fair and equitable 

allocation of securities prices to 

accounts, and provide for crossing of 

buy and sell orders on a fair and 

equitable basis. 

• 12 CFR 12.7(a)(4) requires certain 

national bank officers and employees 

involved in the securities trading 

process to report to the bank all 

personal transactions in securities made 

by them or on their behalf in which they 

have a beneficial interest. 

• 12 CFR 151.150 requires certain 

Federal savings association officers and 

employees to report personal 

transactions they make or that are made 

on their behalf in which they have a 

beneficial interest. 

• 12 CFR 12.8 requires a national 

bank seeking a waiver of one or more of 

the requirements of §§ 12.2 through 12.7 

to file a written request for waiver with 

the OCC. 

Type of Review: Regular. 

Affected Public: Individuals; 

Businesses or other for-profit. 

Estimated Number of Respondents: 

399. 

Estimated Frequency of Response: On 

occasion. 

Estimated Total Annual Burden: 

2,315 hours. 

Comments submitted in response to 

this notice will be summarized and 

included in the request for OMB 

approval. All comments will become a 

matter of public record. Comments are 

invited on: 

(a) Whether the collection of 

information is necessary for the proper 

performance of the functions of the 

OCC, including whether the information 

has practical utility; 

(b) The accuracy of the OCC’s 

estimate of the burden of the collection 

of information; 

(c) Ways to enhance the quality, 

utility, and clarity of the information to 

be collected; 

(d) Ways to minimize the burden of 

the collection on respondents, including 

through the use of automated collection 

techniques or other forms of information 

technology; and 

(e) Estimates of capital or start-up 

costs and costs of operation, 

maintenance, and purchase of services 

to provide information. 

Dated: March 2, 2015. 

Stuart E. Feldstein, 

Director, Legislative and Regulatory Activities 

Division. 

[FR Doc. 2015–05154 Filed 3–5–15; 8:45 am] 

BILLING CODE 4810–33–P 

DEPARTMENT OF VETERANS 

AFFAIRS 

Notice of Intent To Grant an Exclusive 

License 

AGENCY: Office of Research and 

Development, Department of Veterans 

Affairs. 

ACTION: Notice of Intent. 

SUMMARY: Notice is hereby given that 

the Department of Veterans Affairs, 

Office of Research and Development, 

intends to grant to Rubicon 

Biotechnology, LLC, 26212 Dimension 

Dr. Suite 260, Lake Forest, CA 92630, 

USA, an exclusive license to practice 

the following: U.S. Patent Application 

Serial No. 13/815,829 (‘‘ANTIBODYMEDIATED TRANSDUCTION OF HEAT 

SHOCK PROTEINS INTO LIVING 

CELLS’’), filed March 15, 2013, which 

claimed the priority of U.S. Serial No. 

61/618,594, filed March 30, 2012. 

Copies of the published patent 

applications may be obtained from the 

U.S. Patent and Trademark Office at 

www.uspto.gov. 

DATES: Comments must be received 15 

days from the date of this published 

Notice. 

ADDRESSES: Written comments may be 

submitted through www.regulations.gov; 

by mail or hand-delivery to the Director, 

Regulations Management (02REG), 

Department of Veterans Affairs, 810 

Vermont Avenue NW., Room 1068, 

Washington, DC, 20420; or by fax to 

(202) 273–9026. Copies of comments 

received will be available for public 

inspection in the Office of Regulation 

Policy and Management, Room 1063B, 

between the hours of 8:00 a.m. and 4:30 

p.m., Monday through Friday (except 

holidays). Call (202) 461–4902 for an 

appointment (this is not a toll-free 

number). In addition, during the 

comment period, comments may be 

viewed online through the Federal 

Docket Management System at http://

www.regulations.gov. 

FOR FURTHER INFORMATION CONTACT: Dr. 

Lee A. Sylvers, Technology Transfer 

Specialist, Office of Research and 

Development (10P9TT), Department of 

Veterans Affairs, 810 Vermont Avenue 

NW., Washington, DC, 20420, (202) 

443–5646 (this is not a toll-free 

number). 

SUPPLEMENTARY INFORMATION: It is in the 

public interest to so license these 

inventions, as Rubicon Biotechnology, 

LLC submitted a complete and sufficient 

application for a license. The 

prospective exclusive license will be 

royalty-bearing and will comply with 

the terms and conditions of 35 U.S.C. 

209 and 37 CFR 404.7. 

Signing Authority 

The Secretary of Veterans Affairs, or 

designee, approved this document and 

authorized the undersigned to sign and 

submit the document to the Office of the 

Federal Register for publication 

electronically as an official document of 

the Department of Veterans Affairs. Jose 

D. Riojas, Chief of Staff, approved this 

document on March 2, 2015 for 

publication. 

Approved: March 3, 2015. 

Michael Shores, 

Regulation Policy and Management, Office 

of General Counsel. 

[FR Doc. 2015–05209 Filed 3–5–15; 8:45 am] 

BILLING CODE 8320–01–P 

mstockstill on DSK4VPTVN1PROD with NOTICES